The results of the Phase III EMBER-3 trial of imlunestrant, a next-generation oral selective oestrogen receptor degrader (SERD) for patients with hormone receptor-positive breast cancer in ER-positive, HER2-negative advanced breast cancer (ABC), were presented at the SABCS. The study shows that patients with an ESR1 mutation in particular benefit.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)
Diagnosis at an early stage, prognostic classifications and outlook
- Case report: Drug-induced hepatitis
Rare side effect of tirzepatide therapy
- Plea for sex-specific neurology
Migraine in men: underdiagnosed, underestimated, under-researched
- Prurigo nodularis
Retrospective analyses of large data sets from everyday practice
- Public Health
Outpatient care in Switzerland: situation report
- Practice Management
Improved quality of care aims for satisfied patients
- Chemsex - MSM, sex, chrystal meth & co.
Medical and psychosocial perspectives
- Bladder cancer